This Article Full Text Full Text (PDF) All Versions of this Article: 90/5/3089    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaltsas, G. A. Articles by Grossman, A. B. Search for Related Content PubMed PubMed Citation Articles by Kaltsas, G. A. Articles by Grossman, A. B. Pubmed/NCBI databases Substance via MeSH Related Collections Neuroendocrinology and Pituitary Endocrine Oncology

Diagnosis and Management of Pituitary Carcinomas

Department of Endocrinology, St. Bartholomew’s Hospital (G.A.K., A.B.G.), London ECIA 7BE, United Kingdom; Department of Neurosurgery, University of Goettingen (P.N., M.B.), 37075 Goettingen, Germany; and Department of Pathology, George Gennimatas Hospital (G.K.), 11527 Athens, Greece

Address all correspondence and requests for reprints to: Dr. A. B. Grossman, Department of Endocrinology, St. Bartholomew’s Hospital, London ECIA 7BE, United Kingdom. E-mail: a.b.grossman{at}qmul.ac.uk.

Pituitary carcinomas are rare, making up some 0.2% of all pituitary tumors, but represent a particular challenge to clinical practice. The diagnosis of a pituitary carcinoma requires evidence of metastatic disease, either outside the central nervous system (CNS) or as separate noncontiguous foci within the CNS. They may present as typical pituitary adenomas, which reveal their malignant character only as time progresses, or as peculiarly aggressive tumors ab initio. Recent changes in histopathological classification have clarified many of the features of such tumors, including immunohistochemical staining for Ki-67 and p53, but to date none has been found to be pathognomonic. The majority of carcinomas are secretory, usually arising from corticotroph tumors or prolactinomas, but all histological types and secretory patterns are represented. Treatment is by surgery, transsphenoidal wherever possible, and conventional and stereotactic radiotherapy, but ultimately, a plethora of therapies may be required, including various attempts at medical therapy. Chemotherapy in some instances probably prolongs survival, but, in general, their progress from the diagnosis of carcinomatous changes is progressive and inexorable. However, we do not believe there will be any real prospect of long-term survival until the development and use of therapies targeted at specific molecular abnormalities.

This article has been cited by other articles:

				A. Ribeiro-Oliveira Jr, G. Franchi, B. Kola, P. Dalino, S. V. B. Pinheiro, N. Salahuddin, M. Musat, M. I Goth, S. Czirjak, Z. Hanzely, et al. Protein western array analysis in human pituitary tumours: insights and limitations Endocr. Relat. Cancer, December 1, 2008; 15(4): 1099 - 1114. [Abstract] [Full Text] [PDF]

				G. Vlotides, E. Siegel, I. Donangelo, S. Gutman, S.-G. Ren, and S. Melmed Rat Prolactinoma Cell Growth Regulation by Epidermal Growth Factor Receptor Ligands Cancer Res., August 1, 2008; 68(15): 6377 - 6386. [Abstract] [Full Text] [PDF]

				A. Wierinckx, C. Auger, P. Devauchelle, A. Reynaud, P. Chevallier, M. Jan, G. Perrin, M. Fevre-Montange, C. Rey, D. Figarella-Branger, et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors Endocr. Relat. Cancer, September 1, 2007; 14(3): 887 - 900. [Abstract] [Full Text] [PDF]

				M. Kars, F. Roelfsema, J. A Romijn, and A. M Pereira Malignant prolactinoma: case report and review of the literature. Eur. J. Endocrinol., October 1, 2006; 155(4): 523 - 534. [Abstract] [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				R. L Brown, T. Muzzafar, R. Wollman, and R. E Weiss A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur. J. Endocrinol., May 1, 2006; 154(5): 639 - 643. [Abstract] [Full Text] [PDF]